APPOINTMENTS

At these trade fairs and events are presented the MICRONAUT products by our sales partner sifin


06.02.-09.02.2017
MedLab | Dubai

05.03.-08.03.2017
DGHM & VAAM | Wuerzburg

22.04.-25.04.2017
ECCMID | Wien

27.04.-29.04.2017
BAEMI | Kloster Banz

20.06.-21.06.2017
Symposium Fast Methods| Lemgo

30.07.-03.08.2017
AACC | San Diego

13.09.-15.09.2017
AVID Bacteriology | Kloster Banz

20.09. - 23.09.2017
DGU (MICRONAUT) | Dresden

13.11.-16.11.2017
MEDICA | Düsseldorf

07.12.-09.12.2017
Mauch/KMIS | Berlin


MERLIN AT A GLANCE

Spend 3 minutes for deeper insights:

NEWS

MERLIN becomes Bruker's Center of Excellence for MALDI Biotyper-based AST

Bruker acquires MERLIN to add Selected Antibiotic Resistence and Susceptability Testing to its MALDI Biotyper® Microbial Identification Platform

26.07.2017  |  Dr. Esther Pfeil, Managing Director of MERLIN Diagnostika GmbH, commented this acquisition: "We are very pleased to be part of Bruker's microbiology business now, as we have been collaborating with Bruker already for several years. Our product and service offerings in the field of antibiotic susceptibility testing (AST) complement the MALDI Biotyper system for fast and efficient microbial identification. With our proven expertise in the field of AST, we aim to accelerate further assay additions to the MBT-STAR™ consumables portfolio for selected, rapid antibiotic resistance and susceptibility testing on the MALDI Biotyper."

MERLIN will continue to serve all existing collaboration and distribution partners, as well as all OEM customers and end customers after the acquisition.

Further details about MERLIN’s acquisition by Bruker are provided in this press release.

MERLIN's website relaunch

05.04.2017  |  It's done - we are glad about our new website!

It is not only more modern in its design, but also easier to use on all devices.

In addition, this website is safer from hacker attacks. What this means, we had unfortunately learned at our previous system. We apologize to our customers and business partners for the fact that our product information was not available or updated for a short while.

We would appreciated your feedback about what you like, or what you consider to be worthwhile or what is missing. We are looking forward to any of your suggestions.

Dr. Esther Pfeil elected as a member of the German CCI General Assembly

01.01.2017  |  Last autumn, Dr. Esther Pfeil, Managing Director of MERLIN Diagnostika GmbH, took part in the election to the General Assembly of the chamber of commerce and industry Bonn / Rhein-Sieg. Since January 1st, 2017, she is representing the interests of the manufacturing industry in the Rhein-Sieg area for five years at the General Assembly. Dr. Pfeil decided to present herself as a candidate "since I am a managing director of an SME, I would like to take responsibility for the strengthening of small and medium-sized enterprises (SMEs) and their employees in our region. Subjects, of which I feel touched and which I would like to move forward, are the enhancement of market ability through innovation, the expansion of existing training and development programs to promote skilled workers, and the reconcilability of family and work."

 

 

EUCAST warning regarding Colistin susceptibility testing

28.11.2016 | Thanks to our microdilution procedure, EUCAST recommends our MICRONAUT products for Colistin testing!

More information about the difficulties in the EUCAST Colistin susceptibility testing

MICRONAUT-UR | update with the new antibiotic Mecillinam

19.10.2016  |  The plate MICRONAUT-UR, which is used in the bacteriological laboratory diagnostics for urology, is from now on available with an improved antibiotics spectrum. It has been enriched by the new antibiotic Mecillinam.

NRW subsidies for the joint research project "PathoSept"

MERLIN is among the winners in the key market competition LifeSciences.NRW

01.08.2016 | MERLIN Diagnostika is one of the winners of the first round in the key market competition LifeSciences.NRW: Referees voted for the joint research project "PathoSept", which is intended to save many lives by rapidly diagnosing threatening infections.


In the key market competition LifeSciences.NRW, 10 joint projects were selected from 51 contest entries, which will be funded with a total of 19.3 million euros.

"Winner is also our project 'PathoSept', with which we want to create a diagnostic complete system under the coordination of the Fraunhofer Institute for Applied Information Technology. It very quickly identifies pathogenic agents of life-threatening infections and simultaneously allows a quantitative determination of the antibiotic resistance profile. Based on these results, it can be initiated a targeted individual antibiotic therapy no later than nine hours", says Dr. Esther Pfeil, Managing Director of MERLIN Diagnostika.

In addition to the Fraunhofer Institute and MERLIN, the companies Carpegen GmbH, based in Münster, and Jüke Systemtechnik GmbH as well as the university clinics of Aachen and Bonn, belong to the network. The volume of this project is about 3.5 million euros.

Every year, more than 56,000 people die from sepsis in Germany, one of the most severe bacterial infections that can be even simply caused by a purulent tooth. Currently, the time between suspected diagnosis and targeted therapy can last up to five days, and infections with multiresistant pathogens can not be adequately treated. PathoSept is intended to open up the reliable diagnosis after nine hours, thus significantly reducing the high mortality rate, but above all the new generation and spread of multiresistant pathogens, as well as the intensive medical costs. With this an infection can be treated very early in the process and very specifically.

MERLIN has already made essential preparations for this project because we are specialized in the development, validation and marketing of various microbiological diagnostic systems for the qualitative and quantitative detection of microbial antibiotic resistance. MERLIN's diagnostic systems for quantitative susceptibility testing allow the determination of the minimum inhibitory concentration (MIC value) in accordance with the normative requirements. These systems are supplemented by phenotypic detection methods for the detection of clinically and epidemiologically relevant resistance mechanisms. MERLIN also has a great expertise in the handling of antimicrobial agents, which are meaningful in the validation of the manufacture, packaging, storage and application of antibiotic-containing diagnostics. "These are core competencies that make a decisive contribution to the successful implementation of the joint research project," emphasizes Dr. Esther Pfeil.

MERLIN is continuing the development of its products and processes, taking into account sustainability as well as environmental and economic aspects, with the aim of implementing the Antibiotic Stewardship for the rational use of the anti-infectives.

 

 

MICRONAUT-S | first AST product with the new antibiotics combinations of Ceftazidim/Avibactam and Ceftolozan/Tazobactam

24.05.2016 | MICRONAUT-S MDR MRGN Screening, the updated MIC plate for the susceptibility testing of multi-resistant gramnegative bacteria (multidrug resistance phenotype), has been enriched with these new features:

  • Expanded antibiotic spectrum by introducing the new antibiotic combinations Ceftazidim / Avibactam and Ceftolozan / Tazobactam
  • Expanded antibiotic spectrum by introducing Meropenem screening concentrations for improved detection of OXA-48 like type D-Carbapenemases

MICRONAUT-S MDR MRGN Screening provides, based on the microdilution method, the phenotypic detection of clinically relevant resistance mechanisms in enterobacteria and nonfermenters, including the detection of Cephalosporinases and Carbapenemases.

MICRONAUT-S ß-Lactamases | optimized detection of OXA-48

16.03.2016 | The phenotypic detection of multiple ß-Lactamases (multiple resistance determinants) in the single test system has been extended:

MICRONAUT-S β-Lactamases provides, based on the microdilution method, the phenotypic detection  of clinically relevant cephalosporinases and carbapenemases in entero-bacteria and non-fermenters.

  • Detection of OXA-48 like type D carbapenemases by the determination of high-level Temocillin resistance
  • Detection of low-level carbapenem resistance by introduction of Ertapenem / Meropenem screening concentrations

The layout of these special plates is available upon request.

The Medical Laboratory Bremen talks about ASTroID

Enhanced reproducibility and greater accuracy of results through automated, simultaneous AST and MALDI-TOF workflow

Gain a deeper insight here, why our ASTroID application is highly appreciated by the experts.